163 related articles for article (PubMed ID: 37014183)
1. Plasma extracellular vesicle transcriptomics identifies CD160 for predicting immunochemotherapy efficacy in lung cancer.
Liao J; Lai H; Liu C; Zhang X; Ou Q; Li Q; Li Y; Wang Z; Liu C; Wu X; Wang H; Yu H; Sun S; Zhao X; Hu Z; Zhang Y; Lin Y; Yu B; Huang S; Wang J
Cancer Sci; 2023 Jul; 114(7):2774-2786. PubMed ID: 37014183
[TBL] [Abstract][Full Text] [Related]
2. ANK2 as a novel predictive biomarker for immune checkpoint inhibitors and its correlation with antitumor immunity in lung adenocarcinoma.
Zhang W; Shang X; Liu N; Ma X; Yang R; Xia H; Zhang Y; Zheng Q; Wang X; Liu Y
BMC Pulm Med; 2022 Dec; 22(1):483. PubMed ID: 36539782
[TBL] [Abstract][Full Text] [Related]
3. Selective poly adenylation predicts the efficacy of immunotherapy in patients with lung adenocarcinoma by multiple omics research.
Wu L; Zhong Y; Yu X; Wu D; Xu P; Lv L; Ruan X; Liu Q; Feng Y; Liu J; Li X
Anticancer Drugs; 2022 Oct; 33(9):943-959. PubMed ID: 35946526
[TBL] [Abstract][Full Text] [Related]
4. Expanded antigen-experienced CD160
Bozorgmehr N; Okoye I; Oyegbami O; Xu L; Fontaine A; Cox-Kennett N; Larratt LM; Hnatiuk M; Fagarasanu A; Brandwein J; Peters AC; Elahi S
J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33931471
[TBL] [Abstract][Full Text] [Related]
5. Plasma extracellular vesicle microRNA profiling and the identification of a diagnostic signature for stage I lung adenocarcinoma.
Gao S; Guo W; Liu T; Liang N; Ma Q; Gao Y; Tan F; Xue Q; He J
Cancer Sci; 2022 Feb; 113(2):648-659. PubMed ID: 34837453
[TBL] [Abstract][Full Text] [Related]
6. Single-cell transcriptome analysis revealed a suppressive tumor immune microenvironment in EGFR mutant lung adenocarcinoma.
Yang L; He YT; Dong S; Wei XW; Chen ZH; Zhang B; Chen WD; Yang XR; Wang F; Shang XM; Zhong WZ; Wu YL; Zhou Q
J Immunother Cancer; 2022 Jan; 10(2):. PubMed ID: 35140113
[TBL] [Abstract][Full Text] [Related]
7. CD160 isoforms and regulation of CD4 and CD8 T-cell responses.
El-Far M; Pellerin C; Pilote L; Fortin JF; Lessard IA; Peretz Y; Wardrop E; Salois P; Bethell RC; Cordingley MG; Kukolj G
J Transl Med; 2014 Sep; 12():217. PubMed ID: 25179432
[TBL] [Abstract][Full Text] [Related]
8. Circulating MicroRNAs and Extracellular Vesicle-Containing MicroRNAs as Response Biomarkers of Anti-programmed Cell Death Protein 1 or Programmed Death-Ligand 1 Therapy in NSCLC.
Shukuya T; Ghai V; Amann JM; Okimoto T; Shilo K; Kim TK; Wang K; Carbone DP
J Thorac Oncol; 2020 Nov; 15(11):1773-1781. PubMed ID: 32565389
[TBL] [Abstract][Full Text] [Related]
9. A panel of miRNAs derived from plasma extracellular vesicles as novel diagnostic biomarkers of lung adenocarcinoma.
Yao B; Qu S; Hu R; Gao W; Jin S; Liu M; Zhao Q
FEBS Open Bio; 2019 Dec; 9(12):2149-2158. PubMed ID: 31677346
[TBL] [Abstract][Full Text] [Related]
10. Differential and tumor-specific expression of CD160 in B-cell malignancies.
Farren TW; Giustiniani J; Liu FT; Tsitsikas DA; Macey MG; Cavenagh JD; Oakervee HE; Taussig D; Newland AC; Calaminici M; Bensussan A; Jenner M; Gribben JG; Agrawal SG
Blood; 2011 Aug; 118(8):2174-83. PubMed ID: 21715317
[TBL] [Abstract][Full Text] [Related]
11. Targeted sequencing of plasma cell-free DNA to predict response to PD1 inhibitors in advanced non-small cell lung cancer.
Guibert N; Jones G; Beeler JF; Plagnol V; Morris C; Mourlanette J; Delaunay M; Keller L; Rouquette I; Favre G; Pradines A; Mazieres J
Lung Cancer; 2019 Nov; 137():1-6. PubMed ID: 31518912
[TBL] [Abstract][Full Text] [Related]
12. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
[TBL] [Abstract][Full Text] [Related]
13. Combination of tumor mutation burden and immune infiltrates for the prognosis of lung adenocarcinoma.
Zhao Z; He B; Cai Q; Zhang P; Peng X; Zhang Y; Xie H; Wang X
Int Immunopharmacol; 2021 Sep; 98():107807. PubMed ID: 34175739
[TBL] [Abstract][Full Text] [Related]
14. Serum exosomal miR-16-5p functions as a tumor inhibitor and a new biomarker for PD-L1 inhibitor-dependent immunotherapy in lung adenocarcinoma by regulating PD-L1 expression.
Chen HL; Luo YP; Lin MW; Peng XX; Liu ML; Wang YC; Li SJ; Yang DH; Yang ZX
Cancer Med; 2022 Jul; 11(13):2627-2643. PubMed ID: 35347894
[TBL] [Abstract][Full Text] [Related]
15. Possible pathogenic role of the transmembrane isoform of CD160 NK lymphocyte receptor in paroxysmal nocturnal hemoglobinuria.
Giustiniani J; Alaoui SS; Marie-Cardine A; Bernard J; Olive D; Bos C; Razafindratsita A; Petropoulou A; de Latour RP; Le Bouteiller P; Bagot M; Socié G; Bensussan A
Curr Mol Med; 2012 Feb; 12(2):188-98. PubMed ID: 22172098
[TBL] [Abstract][Full Text] [Related]
16. Prognostic value of SEC61G in lung adenocarcinoma: a comprehensive study based on bioinformatics and in vitro validation.
Zheng Q; Wang Z; Zhang M; Yu Y; Chen R; Lu T; Liu L; Ma J; Liu T; Zheng H; Li H; Li J
BMC Cancer; 2021 Nov; 21(1):1216. PubMed ID: 34774014
[TBL] [Abstract][Full Text] [Related]
17. Baseline extracellular vesicle TGF-β is a predictive biomarker for response to immune checkpoint inhibitors and survival in non-small cell lung cancer.
de Miguel-Perez D; Russo A; Gunasekaran M; Buemi F; Hester L; Fan X; Carter-Cooper BA; Lapidus RG; Peleg A; Arroyo-Hernández M; Cardona AF; Naing A; Hirsch FR; Mack PC; Kaushal S; Serrano MJ; Adamo V; Arrieta O; Rolfo C
Cancer; 2023 Feb; 129(4):521-530. PubMed ID: 36484171
[TBL] [Abstract][Full Text] [Related]
18. Elevated Expression of CD160 and 2B4 Defines a Cytolytic HIV-Specific CD8+ T-Cell Population in Elite Controllers.
Pombo C; Wherry EJ; Gostick E; Price DA; Betts MR
J Infect Dis; 2015 Nov; 212(9):1376-86. PubMed ID: 25883386
[TBL] [Abstract][Full Text] [Related]
19. [Expression of CD160 in natural killer (NK) cells from patients with active tuberculosis and its relationship with cell functions].
Yang B; Zhai F; An H; Cao Z; Liu Y; Wang R; Cheng X
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2022 Oct; 38(10):918-924. PubMed ID: 36163624
[TBL] [Abstract][Full Text] [Related]
20. CD160 expression on CD8
Liu S; Zhang W; Liu K; Wang Y
Cancer Immunol Immunother; 2020 May; 69(5):789-797. PubMed ID: 32055919
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
